CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $13.73M, lower than 95% of all stocks globally
- PositionPrice-to-book is 1.02×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
991.61MUSDvs all stocks (USD)
Revenue (TTM)
13.73MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.51xvs all stocks
52-Week Change
-37.65%vs all stocks
Market Capitalization
991.61MUSDvs all stocks (USD)
Enterprise Value
31.18MUSDvs all stocks (USD)
Forward P/E
-5.87xvs Biotechnology peers
Price to Sales (TTM)
70.34xvs Biotechnology peers
Price to Book (MRQ)
1.02xvs Biotechnology peers
Enterprise to Revenue
2.27xvs Biotechnology peers
Enterprise to EBITDA
-0.2010xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-916.50%vs Biotechnology peers
Return on Assets (TTM)
-9.44%vs Biotechnology peers
Return on Equity (TTM)
-11.72%vs Biotechnology peers
Revenue (TTM)
13.73MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2210USDUpdated Jul 19, 2026Gross Profit (TTM)
-113.92MUSDvs all stocks (USD)
EBITDA (TTM)
-155.00MUSDvs all stocks (USD)
Net Income (TTM)
-114.48MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-77.55MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-54.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
10.00MUSDFY2025 · Dec 31, 2025Operating Income
-157.67MUSDvs all stocks (USD)
Pre-tax Income
-113.63MUSDFY2025 · Dec 31, 2025Net Income
-113.63MUSDFY2025 · Dec 31, 2025EBIT
-157.67MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-155.64MUSDFY2025 · Dec 31, 2025Research & Development
125.90MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
44.04MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-113.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-70.12MUSDFY2025 · Dec 31, 2025Free Cash Flow
-71.17MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
53.15MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-113.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.03MUSDFY2025 · Dec 31, 2025Stock-based Compensation
40.22MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
977.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
274.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.04MUSDFY2025 · Dec 31, 2025Purchase of Investments
-705.22MUSDFY2025 · Dec 31, 2025Sale of Investments
405.28MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-300.98MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-347.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-347.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
60.87MSharesUpdated Jul 19, 2026Float Shares
39.13MSharesUpdated Jul 19, 2026Shares Short
7.11MSharesUpdated Jul 19, 2026Short Ratio
5.37daysvs all stocks
Short % of Shares Outstanding
14.93%vs all stocks
% Held by Insiders
1.70%vs all stocks
% Held by Institutions
102.80%vs all stocks
Total Cash (MRQ)
956.39MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
15.68USDUpdated Jul 19, 2026Total Debt (MRQ)
21.57MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0229xvs Biotechnology peers
Current Ratio (MRQ)
17.01xvs Biotechnology peers
Book Value per Share (MRQ)
15.47USDUpdated Jul 19, 2026Total Assets
1.00BUSDvs all stocks (USD)
Total Current Assets
975.89MUSDFY2025 · Dec 31, 2025Total Liabilities
44.74MUSDFY2025 · Dec 31, 2025Total Non-current Assets
25.68MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
19.75MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
52.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
914.23MUSDFY2025 · Dec 31, 2025Accounts Payable
4.97MUSDFY2025 · Dec 31, 2025Short-term Debt
2.39MUSDFY2025 · Dec 31, 2025Long-term Debt
19.75MUSDFY2025 · Dec 31, 2025Common Stock (Book)
60.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-351.38MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
956.82MUSDvs all stocks (USD)
52-Week Low
12.12USDUpdated Jul 19, 202652-Week High
35.34USDUpdated Jul 19, 202652-Week Change
-37.65%vs all stocks
Beta
2.51xvs all stocks
50-Day MA
14.60USDUpdated Jul 19, 2026200-Day MA
17.32USDUpdated Jul 19, 2026Avg 10-Day Volume
922.79KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.24MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.84USDUpdated Jul 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.02×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 1.02Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $13.73M, lower than 95% of all stocks globallySignificant
Revenue (USD): 13,733,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Imax China Holding, Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Century Wind Power Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Zhuzhou Hongda Electronics Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity